GlassScriptPhysician profile
John T Reynolds
NPI 1417027988
$1,610.73
in general payments reported to CMS, 2019-2025
18 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.00 · 2021: $207 · 2022: $535 · 2023: $619 · 2024: $128 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.12 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $403.37 | 2022-2023 | Opdivo |
| Celgene Corporation | $250.27 | 2019-2025 | Reblozyl |
| Myriad Genetic Laboratories, INC. | $142.33 | 2022-2023 | Myrisk |
| Janssen Biotech, INC. | $115.67 | 2022-2023 | Darzalex |
| Eisai INC. | $111.29 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.82 | 2022-2023 | Ninlaro |
| Myovant Sciences INC. | $95.32 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $94.74 | 2022 | |
| Seagen INC. | $68.45 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $57.67 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $54.67 | 2022 | |
| Cti Biopharma Corp. | $33.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.89 | 2023 | |
| Mylan Institutional INC. | $19.71 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $14.66 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $14.11 | 2023 | |
| Daiichi Sankyo INC. | $12.97 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.